Results 101 to 110 of about 7,548 (263)

Probability of Achieving Glycemic Control with Basal Insulin in Patients with Type 2 Diabetes in Real-World Practice in the USA [PDF]

, 2018
Introduction: Basal insulin (BI) plays an important role in treating type 2 diabetes (T2D), especially when oral antidiabetic (OAD) medications are insufficient for glycemic control.
A Stokes, AJ Garber, American Diabetes Association, D Mauricio, EM Heintjes, IM Stratton, J Gordon, K Esposito, K Hermansen, K Khunti, K Khunti, L Berard, M Peyrot, N Wu, O Steen, P Dandona, PA Levin, S Vijan, SB Harris, SD Lin, SE Inzucchi, SG Kim, SI McFarlane, V Valentine, WD Strain, WH Polonsky, X Cai   +26 more
core   +2 more sources

A pilot study comparing the CGM-assessed glycemic profiles of patients with type 1 diabetes on insulin degludec and insulin glargine [PDF]

, 2016
Akio Kuroda, Miho Tsuruo, Nanako Aki, Takeshi Kondo, Yukari Oguro, Motoyuki Tamaki, Ken‐ichi Aihara, Itsuro Endo, Toshio Matsumoto, Masahiro Abe, Munehide Matsuhisa   +10 more
openalex   +1 more source

Second Generation Basal Insulin, Degludec, in the Management of Diabetes; Consensus Report

, 2023
Saud Alsifri, Abdullah Alshahrani, Mohammed Aldawish, Khalid Alyahia, Bandar Alharbi, Horeya Moloy, Ali Alrumiah, Marc Evans, Samia Bokhari, Emad R. Issak   +9 more
openalex   +1 more source

Effects of Aerobic Exercise on Systemic Insulin Degludec Concentrations in People with Type 1 Diabetes [PDF]

, 2021
David Herzig, Michael Groessl, Mario Álvarez‐Martínez, Gemma Reverter‐Branchat, Christos T. Nakas, Christophe Kosinski, Christoph Stettler, Lia Bally   +7 more
openalex   +1 more source

Cost-Effectiveness Analysis of Insulin Detemir Compared to Neutral Protamine Hagedorn (NPH) in Patients with Type 1 and Type 2 Diabetes Mellitus in Spain [PDF]

, 2015
Introduction: An Excel® (Microsoft Corporation) model was adapted to estimate the short-term (1-year) cost effectiveness of insulin detemir (IDet) versus neutral protamine Hagedorn (NPH) insulin in patients initiating insulin treatment with type 1 ...
A Philis-Tsimikas, AE Pontiroli, AJ Lee, AJ Palmer, American Diabet es Association, BM Frier, D Orozco-Beltrán, ER Seaquist, F Alvarez Guisasola, J Smith-Palmer, JA Sacristán, K Eeg-Olofsson, K Hermansen, LF Meneghini, M Brod, M Evans, M Hammer, M Monami, M Ridderstråle, MH Gschwend, PC Bartley, PE Cryer, PE Cryer, SA Williams, SE Inzucchi, UK Hypoglycaemia Study Group, WJ Valentine, WJ Valentine, WJ Valentine   +28 more
core   +2 more sources

Reduced Rates of Hypoglycemia in Type 1 or Type 2 Diabetes After Switching to Insulin Degludec: Results from the Italian Cohort of the ReFLeCT Study [PDF]

, 2020
Gian Paolo Fadini, Carla Giordano, Laura Salvi, Antonio Nicolucci, The REFLECT Italian Study Group   +4 more
openalex   +1 more source

Pediatric diabetes: Potential for insulin degludec

Indian Journal of Endocrinology and Metabolism, 2014
Comprehensive guidelines, published recently by the International Society for Pediatric and Adolescent Diabetes (ISPAD) describe the use of insulin in children and adolescents in great detail.[1] These guidelines provide a bird's eye view of the subject, and also clarify micro management issues, which challenge the pediatric diabetes care provider from
Sanjay Kalra, Ambika Gopalakrishnan Unnikrishnan, Rakesh Sahay   +2 more
openaire   +3 more sources

A1c Reduction and Weight Loss in a Veteran Population Using GLP-1-RAs [PDF]

, 2017
Background: Diabetes mellitus is a metabolic disorder defined by high blood glucose. Glucagon-like peptide-1 receptor agonists (GLP-1-RAs) are a newer class of medications that offer potential 2 to 3 kg weight loss and a 1% to 1.5% decrease in A1c.
Beutel Darrow, Shelby L.
core   +1 more source

A cost-utility analysis of long-acting insulin analogues (detemir, glargine and degludec) for the treatment of adult type 1 diabetes in South Africa

Cost Effectiveness and Resource Allocation
Background Type 1 Diabetes Mellitus (T1DM) is a life-threatening condition that is managed with administered insulin. Intermediate- to long-acting insulin represents the basal insulin constituent of the total insulin used in treating T1DM.
Mark T. Verryn, Susan Cleary
doaj   +1 more source

Effect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agents [PDF]

, 2013
Athena Philis‐Tsimikas, Stefano Del Prato, İlhan Satman, Anuj Bhargava, Mala Dharmalingam, Trine Vang Skjøth, Søren Rasmussen, A. J. Garber   +7 more
openalex   +1 more source